Oppenheimer Begins Coverage on Whitehawk Therapeutics (NASDAQ:WHWK)

Stock analysts at Oppenheimer assumed coverage on shares of Whitehawk Therapeutics (NASDAQ:WHWK) in a note issued to investors on Thursday, MarketBeat reports. The firm set an “outperform” rating and a $6.00 price target on the stock. Oppenheimer’s price target indicates a potential upside of 117.39% from the company’s current price.

A number of other equities analysts have also weighed in on the stock. Jones Trading assumed coverage on shares of Whitehawk Therapeutics in a research report on Monday, December 22nd. They set a “buy” rating and a $7.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research note on Monday, December 29th. Finally, Wall Street Zen cut Whitehawk Therapeutics to a “strong sell” rating in a report on Saturday, November 1st. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Whitehawk Therapeutics has an average rating of “Hold” and an average target price of $6.50.

Whitehawk Therapeutics Price Performance

Whitehawk Therapeutics stock opened at $2.76 on Thursday. The stock has a market capitalization of $130.08 million, a PE ratio of 19.71 and a beta of 0.59. The business has a 50 day simple moving average of $2.61 and a 200-day simple moving average of $2.21. Whitehawk Therapeutics has a 12 month low of $1.39 and a 12 month high of $3.77.

Whitehawk Therapeutics (NASDAQ:WHWK) last released its earnings results on Thursday, November 6th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.25.

Institutional Trading of Whitehawk Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. acquired a new position in shares of Whitehawk Therapeutics in the third quarter worth $2,552,000. Peapod Lane Capital LLC acquired a new stake in shares of Whitehawk Therapeutics in the third quarter valued at $577,000. Dimensional Fund Advisors LP purchased a new position in Whitehawk Therapeutics in the third quarter valued at $84,000. Avoro Capital Advisors LLC acquired a new position in Whitehawk Therapeutics during the 3rd quarter worth $5,414,000. Finally, Suvretta Capital Management LLC purchased a new stake in Whitehawk Therapeutics during the 3rd quarter worth about $7,030,000. 52.08% of the stock is currently owned by hedge funds and other institutional investors.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.